Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
16 February 2017
Deals | France | Capital Markets
Gide advised Lysogene and the banking syndicate comprising Gilbert Dupont and Société Générale on Lysogene's initial public offering and listing on Compartment C of the Euronext regulated market in Paris, which raised approximately EUR 22.6 million by means of a capital increase.
Lysogene is a biotechnology company focused on developing innovative therapies to treat rare and genetic paediatric diseases of the central nervous system.
Combined with the proceeds from the exercise of convertible bonds by the Alto Invest funds, Lysogene raised approximately EUR 25 million. The proceeds of the capital increase will mainly be used to finance the pivotal clinical trial of LYS-SAF302 for the treatment of Sanfilippo Type A, and the phase I/II clinical trial of LYS-GM101 for the treatment of GM1 gangliosidosis.
Gide’s team was led by partner Arnaud Duhamel, assisted by associates Guilhem Richard, Mariléna Gryparis and Juliette Pierre on French law matters, and partner Melinda Arsouze, assisted by associates Scott Logan and Amine Assouad on U.S. law matters. Dechert advised Lysogene on corporate law matters.
